Aptorum Group Limited (APM)

NASDAQ: APM · IEX Real-Time Price · USD
2.17
-0.27 (-10.91%)
At close: Sep 22, 2023, 4:00 PM
2.20
+0.04 (1.62%)
After-hours: Sep 22, 2023, 5:44 PM EDT
-10.91%
Market Cap 9.03M
Revenue (ttm) 1.30M
Net Income (ttm) -9.80M
Shares Out 4.17M
EPS (ttm) -2.75
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,382
Open 2.50
Previous Close 2.43
Day's Range 2.17 - 2.50
52-Week Range 1.72 - 13.00
Beta -0.09
Analysts Strong Buy
Price Target 80.00 (+3,595.15%)
Earnings Date Oct 3, 2023

About APM

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The c... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 18, 2018
Employees 18
Stock Exchange NASDAQ
Ticker Symbol APM
Full Company Profile

Financial Performance

In 2022, Aptorum Group's revenue was $1.30 million, a decrease of -15.95% compared to the previous year's $1.54 million. Losses were -$9.80 million, -60.88% less than in 2021.

Financial Statements

Analyst Forecast

According to one analyst, the rating for APM stock is "Strong Buy" and the 12-month stock price forecast is $80.0.

Price Target
$80.0
(3,595.15% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets

NEW YORK--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announced that it has received an approval letter from the Na...

6 weeks ago - Business Wire

Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company focused on novel technologies including the t...

3 months ago - Business Wire

Aptorum Group Limited Announces Voluntary Delisting from Euronext Paris

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (the “Company”) (NASDAQ:APM, Euronext Paris:APM) announced today that following a comprehensive review of the trading...

3 months ago - Business Wire

Aptorum Group Receives Nasdaq Notification of Minimum Stockholders' Equity Deficiency

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicat...

5 months ago - Business Wire

Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group's Subsidiary Paths Innovations Limited

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Company”), today announced that its wholly owned subsidiary A...

5 months ago - Business Wire

Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “We”), a clinical stage biopharmaceutical company dedicated to...

5 months ago - Business Wire

Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Company”), today announced that it entered into a non-binding...

6 months ago - Business Wire

Aptorum Group Limited and ASP Isotopes Inc. Interviews to Air on Bloomberg U.S. on the RedChip Money Report(R)

ORLANDO, FL / ACCESSWIRE / March 17, 2023 / RedChip Companies will air new interviews with Aptorum Group Limited (Nasdaq:APM, Euronext Paris:APM) and ASP Isotopes Inc. (Nasdaq:ASPI) on The RedChip Mon...

Other symbols: ASPI
6 months ago - Accesswire

Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announ...

7 months ago - Business Wire

Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announ...

7 months ago - Business Wire

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group”), a clinical-stage biopharmaceutical company focused on the devel...

7 months ago - Business Wire

Aptorum Group Regains Compliance with Nasdaq Minimum Bid Price and Receives Nasdaq Notification of Minimum Market Value of Publicly Held Shares Deficiency

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicat...

8 months ago - Business Wire

Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News:

8 months ago - Business Wire

Aptorum Group Announces 1-for-10 Reverse Stock Split

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News:

8 months ago - Business Wire

Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News:

9 months ago - Business Wire

Aptorum Group Announces Completion of $3 Million Convertible Note due 2023

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News:

10 months ago - Business Wire

Aptorum Group Announces Offering of $3 Million Convertible Note due 2023

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News:

10 months ago - Business Wire

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

ORLANDO, FL / ACCESSWIRE / November 25, 2022 / RedChip Companies will air a new interview Aptorum Group Limited (NASDAQ:APM)(Euronext Paris:APM), a clinical stage biopharmaceutical company dedicated t...

10 months ago - Accesswire

Aptorum Group Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News:

11 months ago - Business Wire

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 21, 2022

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicat...

11 months ago - Business Wire

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2022

NEW YORK--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) (“Aptorum Group” or the “Company”), a clinical stage biopharmaceutical company dedicated to meeting...

1 year ago - Business Wire

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in Hong Kong

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group”), a clinical-stage biopharmaceutical company focused on the devel...

1 year ago - Business Wire

Aptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) a clinical stage biopharmaceutical company dedicated to tackling unmet medical nee...

1 year ago - Business Wire